For demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development, CCM Duopharma was awarded the Frost & Sullivan Malaysia Excellence Award in the ‘Halal Pharmaceutical Company of the Year – Prescription Pharmaceuticals’ category.

STRENGTHENING OUR WORKFORCE

Employee Engagement

CCM Duopharma’s employees are our most important asset. We strive to provide the best working conditions for all employees regardless of their nationality, race, or gender. Our labour practices focus on leadership quality, employee engagement, knowledge accessibility and learning capacity to enhance our employees’ competencies and help drive the organisation towards achieving its corporate vision and objectives.

Following the rollout of more effective employee engagement activities, employee sentiment has improved considerably as seen in the results of the latest bi-annual Employee Engagement Survey conducted in 2017. This survey reflected an 11% increase in positive employee sentiment to 89% as compared to just 78% in 2016. This improvement is crucial as it indicates the growing level of connectedness and motivation of our employees as well as their commitment towards realising the Company’s vision and mission. In recognition of our employee engagement efforts, CCM Duopharma was awarded HR Asia’s “Best Companies to Work for in Asia” for 2017.

Skim Latihan 1Malaysia (“SL1M”) Programme

CCM Duopharma has been supporting the nation’s human capital development efforts through our major shareholders PNB, under the SL1M programme by arranging on-the-job training for unemployed graduates to enhance their employability. In 2017, CCM Duopharma provided on-job-training placements for 28 trainees with four of them being absorbed into the CCM Duopharma workforce.

my Millennial Apprentice Programme (“myMAP”)

CCM Duopharma’s myMAP initiative is a fast-track development programme for young graduates to transform the Company into a talent-powered organisation. The myMAP programme strengthens employee competencies and personal development while preparing them for career paths in line with CCM Duopharma’s strategic direction. In 2017, there were six participants in CCM Duopharma’s myMAP. Since 2015, we have absorbed 12 myMAP participants into our workforce.

Training and Development

To ensure that our employees are highly-skilled and competent, we encourage continuous learning among them by providing various training and certification programmes both internally and externally. To ensure that the Company has the appropriate bench strength to support its growth in the future, the Company has in place the myCareer Acceleration Programme (“myCAP”) and a Talent Management Programme to develop capable employees as successors in the Company.

CCM Duopharma also places great emphasis on workplace diversity. Our Core Values help guide our team of dedicated and committed employees to carry out their tasks professionally, ethically and with integrity. Meanwhile, programmes like Lean Six Sigma, Operational Excellence and Innovation & Quality Convention have translated into cost savings and greater efficiency, paving the way for innovative solutions to ensure the sustainable growth of the business.
CCM Duopharma's Workforce

Total no. of employees at CCM Duopharma

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>1170</td>
<td>1142</td>
<td>1173</td>
<td>1264</td>
</tr>
</tbody>
</table>

Ethnicity at CCM Duopharma

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>Bumiputera</th>
<th>Chinese</th>
<th>Indian</th>
<th>Others</th>
<th>Filipino</th>
<th>Singaporean</th>
<th>Indonesian</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percentage of Employees</td>
<td>61.39%</td>
<td>18.28%</td>
<td>15.59%</td>
<td>0.16%</td>
<td>3.32%</td>
<td>0.79%</td>
<td>0.47%</td>
<td>100%</td>
</tr>
</tbody>
</table>

Percentage of Employees

Breakdown by Ethnicity
Breakdown of Working Levels by Ethnicity

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>Top Management</th>
<th>Senior &amp; Middle Management</th>
<th>Executive</th>
<th>Non-Executive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bumiputera</td>
<td>44.45%</td>
<td>38.83%</td>
<td>54.02%</td>
<td>66.24%</td>
</tr>
<tr>
<td>Chinese</td>
<td>22.22%</td>
<td>41.16%</td>
<td>27.49%</td>
<td>13.10%</td>
</tr>
<tr>
<td>Indian</td>
<td>22.22%</td>
<td>10.83%</td>
<td>11.85%</td>
<td>16.99%</td>
</tr>
<tr>
<td>Others</td>
<td>0.00%</td>
<td>1.67%</td>
<td>0.00%</td>
<td>0.00%</td>
</tr>
<tr>
<td>Filipino</td>
<td>11.11%</td>
<td>4.17%</td>
<td>4.27%</td>
<td>3.03%</td>
</tr>
<tr>
<td>Singaporean</td>
<td>0.00%</td>
<td>1.67%</td>
<td>1.90%</td>
<td>0.32%</td>
</tr>
<tr>
<td>Indonesian</td>
<td>0.00%</td>
<td>1.67%</td>
<td>0.47%</td>
<td>0.32%</td>
</tr>
<tr>
<td>Total</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

Breakdown by Ethnicity

- **Top Management**
  - Bumiputera: 44.45%
  - Chinese: 22.22%
  - Indian: 22.22%
  - Others: 11.11%
  - Filipino: 1.67%
  - Singaporean: 0.00%
  - Indonesian: 0.00%

- **Senior & Middle Management**
  - Bumiputera: 38.83%
  - Chinese: 10.83%
  - Indian: 10.83%
  - Others: 1.67%
  - Filipino: 4.17%
  - Singaporean: 1.67%
  - Indonesian: 1.67%

- **Executive**
  - Bumiputera: 54.02%
  - Chinese: 27.49%
  - Indian: 11.85%
  - Others: 1.67%
  - Filipino: 4.27%
  - Singaporean: 1.90%
  - Indonesian: 0.47%

- **Non-Executive**
  - Bumiputera: 66.24%
  - Chinese: 16.99%
  - Indian: 13.10%
  - Others: 3.03%
  - Filipino: 0.32%
  - Singaporean: 0.32%
  - Indonesian: 0.32%
Breakdown by Gender

<table>
<thead>
<tr>
<th>Gender</th>
<th>Top Management</th>
<th>Senior &amp; Middle Management</th>
<th>Executive</th>
<th>Non-Executive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>88.89%</td>
<td>45.83%</td>
<td>38.39%</td>
<td>51.08%</td>
</tr>
<tr>
<td>Female</td>
<td>11.11%</td>
<td>54.17%</td>
<td>61.61%</td>
<td>48.92%</td>
</tr>
<tr>
<td>Total</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>
Breakdown by Age Group

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Top Management</th>
<th>Senior &amp; Middle Management</th>
<th>Executive</th>
<th>Non-Executive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Below 20 years</td>
<td>0.00%</td>
<td>0.00%</td>
<td>0.00%</td>
<td>1.41%</td>
</tr>
<tr>
<td>20-29 years</td>
<td>0.00%</td>
<td>1.67%</td>
<td>45.50%</td>
<td>30.19%</td>
</tr>
<tr>
<td>30-39 years</td>
<td>0.00%</td>
<td>35.83%</td>
<td>28.91%</td>
<td>36.03%</td>
</tr>
<tr>
<td>40-49 years</td>
<td>44.44%</td>
<td>38.33%</td>
<td>13.74%</td>
<td>20.89%</td>
</tr>
<tr>
<td>50-59 years</td>
<td>55.56%</td>
<td>22.50%</td>
<td>9.95%</td>
<td>10.61%</td>
</tr>
<tr>
<td>&gt; 60 years</td>
<td>0.00%</td>
<td>1.67%</td>
<td>1.90%</td>
<td>0.87%</td>
</tr>
<tr>
<td>Total</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

Keeping People Safe and Healthy

As CCM Duopharma ventures forth, we are mindful of our impact on the world around us and remain deeply committed to the health, safety and well-being of the people who put their trust in our products and the global communities in which we operate. We also continue to work to ensure that our scientific contributions reflect our commitment to safe and healthy workplaces, strong communities as well as responsible and ethical business practices – all the way from our research and development efforts to our manufacturing and distribution activities. All our products incorporate environmental, health and safety design considerations.

All in all, 2017 saw CCM Duopharma making good strides forward on the EES fronts. Further details of our sustainability initiatives can be found in our standalone CCM Duopharma Sustainability Report 2017 which is available on the Company’s website at www.ccmduopharma.com
CALENDAR OF MAJOR EVENTS

2 FEBRUARY 2017
World’s First Halal Certification For Prescriptive Medicine issued by Jakim to CCM Duopharma based on MS24242012 Standards

17 MARCH 2017
MyCAP Graduation Ceremony

3 APRIL 2017
CCM Duopharma partnered Natco and Biocon

13 APRIL 2017
Halal Pharmaceutical Company of the Year – Prescription Pharmaceuticals by Frost & Sullivan

13 APRIL 2017
CHAMPS partnered NASOM to boost Autism awareness

19 - 21 MAY 2017
8th MEMS Annual Congress 2017

22 MAY 2017
CCM Duopharma Biotech Berhad 16th Annual General Meeting
11 JULY 2017
Launch of CHAMPS - Watsons MY CHAMPION Mobile App

17 JULY 2017
Sahabat Korporat Tabung Haji

27 SEPTEMBER 2017
Plant visit to CCMP Bangi led by NPRA for delegates from various Regulatory Agencies

13 OCTOBER 2017
Best Companies To Work For In Asia 2017 Award to CCM Duopharma Biotech Berhad by HR Asia

25 - 26 NOVEMBER 2017
Shariah Investment Fair held at KL Convention Centre

6 DECEMBER 2017
MSWG ASEAN Corporate Governance Recognition 2017 by Minority Shareholder Watchdog Group

15 DECEMBER 2017
Millennial Pharmapreneur Coaching (MPC) programme for USM pharmacy undergraduates
COMPANY SECRETARY
Ibrahim Hussin Salleh (LS0009121)

REGISTERED OFFICE
13th Floor, Menara PNB
201-A, Jalan Tun Razak
50400 Kuala Lumpur
Tel No.: 03-2612 3888
Fax No.: 03-2166 5103

BUSINESS ADDRESS
Lot 2599,
Jalan Seruling 59
Kawasan 3
Taman Klang Jaya
41200 Klang
Selangor Darul Ehsan
Tel No. : 03-3323 2759
Fax No. : 03-3323 3923
Website : www. ccmduopharma. com
E-mail : cs@ ccmduopharma. com

AUDITORS
Messrs. KPMG PLT
Chartered Accountants
Level 10, KPMG Tower
8 First Avenue, Bandar Utama
47800 Petaling Jaya
Selangor Darul Ehsan

PRINCIPAL BANKERS
AmBank (M) Berhad
No.1, Ground Floor, Lorong Sanggul 1F, Bandar Puteri
41000 Klang
Selangor Darul Ehsan

OCBC Bank (Malaysia) Berhad
No.19, Jalan Stesen
41000 Klang
Selangor Darul Ehsan

Sumitomo Mitsui Banking Corporation Malaysia Berhad
Suite 22-03, Level 22
Integra Tower
The Intermark
348 Jalan Tun Razak
50400 Kuala Lumpur

Malayan Banking Berhad
No 7&9, Jalan 9/9C
Section 9
43650 Bandar Baru Bangi
Selangor Darul Ehsan

Hong Leong Bank
68, Lorong Batu Nilam 3A
Bandar Bukit Tinggi
41200 Klang
Selangor Darul Ehsan

SHARE REGISTRAR
Tricor Investor, & Issuing House Service Sdn Bhd
Unit 32-01, Level 32,
Tower A,
Vertical Business Suite,
Avenue 3,
Bangsar South,
No.8, Jalan Kerinchi,
59200 Kuala Lumpur.
Tel No. : 03-2783 9299
Fax No. : 03-2783 9222

STOCK EXCHANGE LISTING
Main Market of Bursa Malaysia Securities Berhad
BOARD OF DIRECTORS

BOARD COMMITTEES
- Audit and Integrity Committee
- Nomination and Remuneration Committee
- Risk Management Committee

CORPORATE STRUCTURE

CCM DUOPHARMA BIOTECH BERHAD (524271-W)

100%
- CCM Pharmaceuticals Sdn. Bhd. (27754-W)
- Sentosa Pharmacy Sdn. Bhd. (69958-V)
- Unique Pharmacy (Penang) Sdn. Bhd. (287046-P)
- CCM Biopharma Sdn. Bhd. (88895-U)
- Negeri Pharmacy Sdn. Bhd. (79732-D)
- Unique Pharmacy (Ipoh) Sdn. Bhd. (145705-T)

100%
- Innovax Sdn. Bhd. (564984-V)

100%
- Duopharma (M) Sendirian Berhad (42491-M)

100%
- Upha Pharmaceutical Manufacturing (M) Sdn. Bhd. (53667-M)

100%
- CCM Pharma Sdn. Bhd. (4672-U)

100%
- CCM Pharmaceuticals (S) Pte. Ltd.

100%
- CCM International (Philippines), Inc.
ENGAGING TEAM COLLABORATION

Our collaborative culture permeates throughout the entire organisation with an engaged team that's eager to take on new projects and embrace change as a challenge to take them to the next level in enhancing productivity and profitability.
TAN SRI DATIN PADUKA SITI SA’DIAH BINTI SH BAKIR

Age
65 years

Gender
Female

Nationality
Malaysian

POSITION ON THE BOARD
Non-Independent
Non-Executive Chairman

DATE OF APPOINTMENT TO
THE BOARD
5 April 2016

MEMBERSHIP OF BOARD
COMMITTEES
• Member, Nomination and Remuneration Committee

DIRECTORSHIPS OF OTHER
PUBLIC COMPANIES AND
LISTED ISSUERS
• KPJ Healthcare Berhad
• Nationwide Express Holdings Berhad
• OSK Holdings Berhad
• Awqaf Holdings Berhad

SECURITIES HOLDINGS IN
THE COMPANY AND ITS
SUBSIDIARIES
None as at 28 March 2018

FAMILY RELATIONSHIP WITH
ANY DIRECTOR AND/OR
MAJOR SHAREHOLDER
None

CONFLICT OF INTEREST WITH
THE COMPANY
None

LIST OF CONVICTIONS FOR
OFFENCES WITHIN THE PAST
5 YEARS AND PARTICULARS
OF ANY PUBLIC SANCTION
OR PENALTY IMPOSED BY
THE RELEVANT REGULATORY
BODIES DURING THE
FINANCIAL YEAR
None

NO. OF BOARD MEETINGS
ATTENDED IN THE FINANCIAL
YEAR
Six (6) out of seven (7) meetings (since date of appointment)

QUALIFICATIONS
• Master of Business Administration, Henley Business School, University of Reading, United Kingdom
• Bachelor in Economics, University of Malaya

WORKING EXPERIENCE AND
OCCUPATION
Tan Sri Datin Paduka Siti Sa’diah Sh Bakir was redesignated as the Non-Independent Non-Executive Chairman of CCM Duopharma Biotech Berhad’s Board on 28 December 2017. Consequently, she relinquished her position as the Senior Independent Director on 28 December 2017.

Tan Sri served as an Independent Non-Executive Director of Chemical Company of Malaysia Berhad from 19 December 2014 until 28 December 2017.

She is an Independent Non-Executive Director of KPJ, redesignated on 1 May 2015 from Non-Independent, Non-Executive Director. Tan Sri served as the Managing Director of KPJ from 1 March 1993 until her retirement on 31 December 2012.

From 1 January 2013 until 31 December 2014, she served as KPJ’s Corporate Advisor. She was the Chairman and Pro-Chancellor of KPJ Healthcare University College ("KPJUC") between 1 August 2011 to 31 December 2016.

Her career with Johor Corporation ("JCorp") commenced in 1974 and she has been directly involved in JCorp’s Healthcare Division since 1978. She was appointed as the Chief Executive of Kumpulan Perubatan Perubatan (Johor) Sdn. Bhd. ("KPJSB"), from 1989 until the listing of KPJ in November 1994.

Committed to promoting excellence in healthcare, Tan Sri is the President of Malaysian Society for Quality in Health ("MSQH"), the national accreditation body for healthcare services, elected since its inception in 1997 to date. She sits on many other councils and committees at the national level, including as a member of the Leadership Development Committee of the Razak School of Government ("RSOG") since 25 November 2013.

In June 2016, she was appointed as the Chairman of Universiti Utara Malaysia, an eminent management university in Malaysia.

She was also the Pro-Chancellor of University Teknologi Malaysia appointed since 1st November 2016.

In 2010, Tan Sri was named the ‘CEO of The Year 2009’ by the New Straits Times Press and the American Express. She has also received many more awards and accolades from 2011 to 2015, due to her contributions to the healthcare industry in Malaysia. She launched her biography entitled “Siti Sa’diah: Driven by Vision, Mission and Passion”, penned by Professor Rokiah Talib, Penerbitan Universiti Kebangsaan Malaysia in 2013.
LEONARD ARIFF
BIN ABDUL SHATAR

Age
53 years

Gender
Male

Nationality
Malaysian

POSITION ON THE BOARD
Group Managing Director

DATE OF APPOINTMENT TO THE BOARD
28 December 2017

FAMILY RELATIONSHIP WITH ANY DIRECTOR AND/OR MAJOR SHAREHOLDER
None

CONFLICT OF INTEREST WITH THE COMPANY
None

LIST OF CONVICTIONS FOR OFFENCES WITHIN THE PAST 5 YEARS AND PARTICULARS OF ANY PUBLIC SANCTION OR PENALTY IMPOSED BY THE RELEVANT REGULATORY BODIES DURING THE FINANCIAL YEAR
None

NO. OF BOARD MEETINGS ATTENDED IN THE FINANCIAL YEAR
None

QUALIFICATIONS
• LLB, Monash University, Melbourne, Australia
• Bachelor of Economics, Monash University, Melbourne, Australia

WORKING EXPERIENCE AND OCCUPATION
Leonard Ariff was appointed as the Group Managing Director of CCM Duopharma Biotech Berhad on 28 December 2017.

Prior to his appointment as the Group Managing Director, he was the Chief Executive Officer of CCM Duopharma Biotech Berhad from 1 January 2008 until 28 December 2017. On 9 January 2015, he was also appointed as the Group Managing Director of Chemical Company of Malaysia Berhad (“CCMB”), and served that position until 28 December 2017. On 9 January 2015, he was also appointed as the Managing Director of Usaha Pharma (M) Sdn. Bhd. (formerly known as Prima Health Pharmacy (Retail) Sdn. Bhd.), CCM’s pharmaceuticals retail arm. He later joined ICI Paints Malaysia Sdn. Bhd. in 2003 as the General Manager and was subsequently appointed as Managing Director in 2005 until 2007, before re-joining the CCMB Group in 2008. He was also the Director of CCMB’s Chemicals Division from October 2014 until December 2015.

He holds a directorships on the boards of PanGen Biotech Inc. (Korea). He also acts as Chair of the School of Business Industry Advisory Board at Monash University Malaysia. He has been appointed to participate in the CEO @ Faculty program by the Malaysia Ministry of Higher Education and has been assigned to Universiti Kebangsaan Malaysia (“UKM”).

He held the position as President of the Malaysian Organisation of Pharmaceutical Industries (“MOPI”) from 2009 to 2014.
Dato' Mohamad Kamarudin Bin Hassan

Age
62 years

Gender
Male

Nationality
Malaysian

POSITION ON THE BOARD
Senior Independent Non-Executive Director

DATE OF APPOINTMENT TO THE BOARD
2 January 2014

MEMBERSHIP OF BOARD COMMITTEES
- Chairman, Nomination and Remuneration Committee
- Member, Audit and Integrity Committee

DIRECTORSHIPS OF OTHER PUBLIC COMPANIES AND LISTED ISSUERS
- ManagePay Systems Berhad
- Malaysian Pacific Industries Berhad
- Lion Diversified Holding Berhad
- Muhibbah Engineering Berhad

SEcurities HOLDINGS IN THE COMPANY AND ITS SUBSIDIARIES
None as at 28 March 2018

FAMILY RELATIONSHIP WITH ANY DIRECTOR AND/OR MAJOR SHAREHOLDER
None

CONFLICT OF INTEREST WITH THE COMPANY
None

LIST OF CONVICTIONS FOR OFFENCES WITHIN THE PAST 5 YEARS AND PARTICULARS OF ANY PUBLIC SANCTION OR PENALTY IMPOSED BY THE RELEVANT REGULATORY BODIES DURING THE FINANCIAL YEAR
None

NO. OF BOARD MEETINGS ATTENDED IN THE FINANCIAL YEAR
Seven (7) out of seven (7) meetings (since date of appointment)

QUALIFICATIONS
- Master of Business Administration (Majoring in Finance), Oklahoma City University
- Bachelor of Economics (Majoring in Business Administration), University of Malaya
- Diploma in Public Management, Institut Tadbiran Awam Malaysia ("INTAN")

WORKING EXPERIENCE AND OCCUPATION
Dato' Mohamad Kamarudin began his career with the Administrative and Diplomatic Service in 1979 with his first posting to the Macro-Economic Division of the Economic Planning Unit in the Prime Minister's Department. In 1987, he was transferred to the Ministry of International Trade and Industry ("MITI") where he had served in various divisions of the Ministry. From 1992 to 1994, he was posted to the Malaysian Embassy in Washington DC as the Economic Counsellor. From January 2006 until his retirement on 31 August 2013, he was seconded to MATRADE as the Deputy Chief Executive Officer.

Dato' Mohamad Kamarudin was appointed as the Senior Independent Director of CCM Duopharma Biotech Berhad with effect from 28 December 2017 following the redesignation of Tan Sri Datin Paduka Siti Sa'diah Binti Sh Bakir as the Non-Independent Non-Executive Chairman.
RAZALEE BIN AMIN

**Age**
64 years

**Gender**
Male

**Nationality**
Malaysian

**POSITION ON THE BOARD**
Independent Non-Executive Director

**DATE OF APPOINTMENT TO THE BOARD**
1 June 2016

**MEMBERSHIP OF BOARD COMMITTEES**
- Chairman, Audit and Integrity Committee

**DIRECTORSHIPS OF OTHER PUBLIC COMPANIES AND LISTED ISSUERS**
- Bank Kerjasama Rakyat Malaysia Berhad
- UMW Oil & Gas Corporation Berhad

**SECURITIES HOLDINGS IN THE COMPANY AND ITS SUBSIDIARIES**
None as at 28 March 2018

**FAMILY RELATIONSHIP WITH ANY DIRECTOR AND/OR MAJOR SHAREHOLDER**
None

**CONFLICT OF INTEREST WITH THE COMPANY**
None

**LIST OF CONVICTIONS FOR OFFENCES WITHIN THE PAST 5 YEARS AND PARTICULARS OF ANY PUBLIC SANCTION OR PENALTY IMPOSED BY THE RELEVANT REGULATORY BODIES DURING THE FINANCIAL YEAR**
None

**NO. OF BOARD MEETINGS ATTENDED IN THE FINANCIAL YEAR**
Seven (7) out of seven (7) meetings (since date of appointment)

**QUALIFICATIONS**
- Chartered Accountant (Malaysia), Malaysian Institute of Accountant
- Certified Public Accountants, The Malaysian Institute of Certified Public Accountants
- Certified Financial Planner, Financial Planning Association of Malaysia
- Diploma in Accounting (Postgraduate), University of Malaya
- Bachelor of Economics (Hons) Accounting, University of Malaya

**WORKING EXPERIENCE AND OCCUPATION**
Razalee began his career with Messrs. Hanafiah Raslan & Mohamad, a Chartered Accountants firm upon graduation. In 1983, he joined Sateras Resources (Malaysia) Berhad as the Group Financial Controller. He then joined MBf Finance Berhad in 1987 and was appointed as the Senior Vice President of the Investment and Acquisitions Division. He left MBf Finance Berhad and subsequently joined Damansara Realty Berhad in 1994 as the Senior General Manager. In 1996, he started his own Chartered Accountants firm, Razalee & Co. where he is currently its Managing Partner.
PUAN SRI DATUK SERI ROHANI PARKASH BINTI ABDULLAH

AGE
62 years

GENDER
Female

NATIONALITY
Malaysian

POSITION ON THE BOARD
Independent Non-Executive Director

DATE OF APPOINTMENT TO THE BOARD
2 August 2016

FAMILY RELATIONSHIP WITH ANY DIRECTOR AND/OR MAJOR SHAREHOLDER
None

CONFLICT OF INTEREST WITH THE COMPANY
None

LIST OF CONVICTIONS FOR OFFENCES WITHIN THE PAST 5 YEARS AND PARTICULARS OF ANY PUBLIC SANCTION OR PENALTY IMPOSED BY THE RELEVANT REGULATORY BODIES DURING THE FINANCIAL YEAR
None

NO. OF BOARD MEETINGS ATTENDED IN THE FINANCIAL YEAR
Six (6) out of seven (7) meetings (since date of appointment)

QUALIFICATIONS
• Master of Business Administration, Oklahoma State University, United States of America
• Diploma in Public Administration, Institut Tadbiran Awam Malaysia ("INTAN")
• Bachelor of Arts (Hons), Universiti Kebangsaan Malaysia
• Diploma Perguruan, Universiti Kebangsaan Malaysia

WORKING EXPERIENCE AND OCCUPATION
Puan Sri was appointed to the Board of CCM Duopharma Biotech Berhad as Independent Non-Executive Director on 2 August 2016.

She obtained her Master of Business Administration from Oklahoma State University, United States of America in 1995.

Her career spanned primarily in the land and regional development and communication and multimedia, human resources and higher education sectors. She was extensively involved in international, policy and development aspects of these sectors and departments and left the government service in 2012 as the Deputy Secretary General of Ministry of Higher Education. She concluded her career in the public sector as a Senior Fellow at University Teknologi Malaysia.

Since mid-2015, Puan Sri has involved herself solely with the corporate sector and her role as the current President (since 2012) of PUSPANITA Kebangsaan (Association of Women Civil Servants and Wives of Civil Servants) which is a charity and volunteer organisation.

MEMBERSHIP OF BOARD COMMITTEES
None

DIRECTORSHIPS OF OTHER PUBLIC COMPANIES AND LISTED ISSUERS
• Nylex (Malaysia) Berhad
• 7-Eleven Malaysia Holdings Berhad
• Symphony Life Berhad

SECURITIES HOLDINGS IN THE COMPANY AND ITS SUBSIDIARIES
None as at 28 March 2018
ZAITON BINTI JAMALUDDIN

Age
58 years

Gender
Female

Nationality
Malaysian

POSITION ON THE BOARD
Independent Non-Executive Director

DATE OF APPOINTMENT TO THE BOARD
1 September 2016

FAMILY RELATIONSHIP WITH ANY DIRECTOR AND/OR MAJOR SHAREHOLDER
None

CONFLICT OF INTEREST WITH THE COMPANY
None

LIST OF CONVICTIONS FOR OFFENCES WITHIN THE PAST 5 YEARS AND PARTICULARS OF ANY PUBLIC SANCTION OR PENALTY IMPOSED BY THE RELEVANT REGULATORY BODIES DURING THE FINANCIAL YEAR
None

NO. OF BOARD MEETINGS ATTENDED IN THE FINANCIAL YEAR
Seven (7) out of seven (7) meetings (since date of appointment)

QUALIFICATIONS
- Bachelor of Pharmacy, Western Australia Institute of Technology
- Diploma in Management, Malaysian Institute of Management
- Master of Business Administration, Keele University, United Kingdom

WORKING EXPERIENCE AND OCCUPATION
Zaiton had accumulated over 20 years of experience in the healthcare and pharmaceutical industry. She began her illustrious career as a pupil pharmacist with the Ministry of Health in 1982. Thereafter, she joined the sales and marketing team of United Italian Trading Corporation in 1984. In 1985, she served as the Assistant Medical Information Manager for the South East Asia Regional Office of Novo Industri A/S. In 1989, when Novo Industri A/S and Nordisk Gentofte A/S merged to become Novo Nordisk A/S, the world’s leading producer of insulin, she was appointed as the Business Development Manager of Malaysia, a post she held until 1993. From 1993 to 1997, she held the position of the Novo Nordisk Country Manager for Malaysia. In 1997, she became the General Manager of Novo Nordisk Pharma (M) Sdn. Bhd. until 2007. During the long stint with Novo Nordisk, Zaiton helped establish and grew the Novo Nordisk business, mainly in insulin and oral diabetes care, haematology and women’s therapy. She held roles in the areas of general management, sales and marketing, business development and training. In addition, she was involved in lobbying and making presentations to the government.

An expert in her field, she was regularly invited to speak on scientific as well as motivational topics. She has served on the board of several organisations throughout her career, namely as member on the MARA Council (2000-2002) and a director on the Board of Malaysian Biotechnology Corporation Sdn. Bhd. (2006 to 2008). She was also the former President of the Pharmaceutical Association of Malaysia (2005 to 2007).

MEMBERSHIP OF BOARD COMMITTEES
- Member, Audit and Integrity Committee
- Member, Risk Management Committee

DIRECTORSHIPS OF OTHER PUBLIC COMPANIES AND LISTED ISSUERS
None

SECURITIES HOLDINGS IN THE COMPANY AND ITS SUBSIDIARIES
None as at 28 March 2018

Annual Report 2017
Dato' Eisah Binti A.Rahman

Age
62 years

Gender
Female

Nationality
Malaysian

POSITION ON THE BOARD
Independent Non-Executive Director

DATE OF APPOINTMENT TO THE BOARD
16 November 2016

MEMBERSHIP OF BOARD COMMITTEES
• Member, Risk Management Committee
• Member, Nomination and Remuneration Committee

DIRECTORSHIPS OF OTHER PUBLIC COMPANIES AND LISTED ISSUERS
None

SECURITIES HOLDINGS IN THE COMPANY AND ITS SUBSIDIARIES
None as at 28 March 2018

FAMILY RELATIONSHIP WITH ANY DIRECTOR AND/OR MAJOR SHAREHOLDER
None

CONFLICT OF INTEREST WITH THE COMPANY
None

LIST OF CONVICTIONS FOR OFFENCES WITHIN THE PAST 5 YEARS AND PARTICULARS OF ANY PUBLIC SANCTION OR PENALTY IMPOSED BY THE RELEVANT REGULATORY BODIES DURING THE FINANCIAL YEAR
None

NO. OF BOARD MEETINGS ATTENDED IN THE FINANCIAL YEAR
Seven (7) out of seven (7) meetings (since date of appointment)

QUALIFICATION
• Bachelor’s Degree in Pharmacy, Curtin University of Technology, Western Australia
• Diploma (Postgraduate) in Medical Microbiology, Institute for Medical Research, Kuala Lumpur
• Master of Science in Pharmaceutical Analysis, University of Manchester, United Kingdom

WORKING EXPERIENCE AND OCCUPATION
Dato’ Eisah served in the Malaysian Ministry of Health as a pharmacist since 1979 and held several key positions throughout her years of service. This included being the Head of Pharmaceutical Microbiology Lab, Head of GMP and Licensing Section, Deputy Director of Centre for Product Registration and eventually the Director of National Pharmaceutical Control Bureau (“NPCB”). In 2007, she was made Director of Pharmacy Enforcement and was promoted to Senior Director of Pharmaceutical Services in 2008, taking charge of the entire pharmacy programme in Malaysia. Also, since 2008, she was the Registrar of the Pharmacy Board of Malaysia.

Throughout her career, she made significant contributions to the pharmacy service and the pharmaceutical sector. She was involved in various national high level committees such as the Ministry of Health’s Steering Committee for National Medicines Policy. She participated in healthcare related conferences serving as an expert on regulatory matters. She has presented major papers on regulatory control locally and internationally.

Internationally, she has held advisory roles in the area of regulations and pharmaceutical quality assurance. She was also involved in the ASEAN harmonisation initiatives for pharmaceuticals, medical devices, cosmetics, traditional medicines and health supplements. She chaired the ASEAN Consultative Committee for Standards and Quality (“ACCSQ”) Pharmaceutical Product Working Group, which was instrumental to the implementation of the ASEAN Common Technical Dossier and the ASEAN Technical Guidelines. She led NPCB to being accepted as the 26th Member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in 2002. Under her leadership, NPCB was designated a Non-OECD Member Adhering to the OECD Mutual Acceptance Data (“OECD-MAD”) System. Also under her helm, the Pharmaceutical Services Division received the Global Anti-Counterfeiting Award 2013 and the Special Innovation Award 2013 for initiatives in combating counterfeit medicines. NPCB is now known as National Pharmaceutical Regulatory Agency (“NPRA”).